Confronta i metodi

	Multiple Sclerosis Walking Scale-12 (MSWS-12)	Scala Rankin Modificata (mRS)	Questionario sulla Qualità della Vita nella Sclerosi Multipla-54 (MSQOL-54)
Campo	Neurologia	Neurologia	Neurologia
Famiglia	Process / pipeline	Process / pipeline	Process / pipeline
Anno di origine	2003	1988	1995
Ideatore	Jeremy C. Hobart, University of Plymouth	Rankin scale original (Rankin, 1957); modified version by van Swieten et al.	Barbara G. Vickrey, UCLA
Tipo	Self-report questionnaire	Clinician-rated ordinal scale	Self-report questionnaire
Fonte seminale	Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36.	van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607.	Vickrey, B. G., Hays, R. D., Genovese, B. J., Myers, L. W., & Ellison, G. W. (1995). Outcomes in Multiple Sclerosis: The Multiple Sclerosis Quality of Life-54 Scale. Health Psychology, 14(1), 34-42.
Alias	MS Walking Scale-12, MSWS	mRS, Rankin Scale, Modified Rankin	MS QoL-54
Correlati	3	4	4
Sintesi	The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation. Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility.	The Modified Rankin Scale is a simple 0-6 ordinal measure of global disability or dependency in patients with stroke and other neurological conditions. Originally developed by Rankin in 1957 and modified by van Swieten and colleagues in 1988, it remains the most widely used global disability outcome in stroke clinical trials and clinical practice. Its simplicity, brevity, and strong prognostic association make it the gold standard for acute stroke outcome measurement and is mandated as a primary endpoint in virtually all stroke therapeutic trials.	The MSQOL-54 is a disease-specific quality-of-life instrument designed to assess the physical and mental burden of multiple sclerosis on patients' daily functioning and well-being. Developed by Vickrey and colleagues in 1995, it combines the widely-used SF-36 generic health questionnaire with 18 MS-specific items to provide comprehensive measurement of QoL in MS populations. This scale is a cornerstone tool in MS clinical research and patient monitoring.